Ignite Creation Date:
2024-05-05 @ 9:28 PM
Last Modification Date:
2024-10-26 @ 10:05 AM
Study NCT ID:
NCT00897910
Status:
TERMINATED
Last Update Posted:
2016-01-11
First Post:
2009-05-09
Brief Title:
Studying T Cells in Blood and Bone Marrow Samples From Patients With Multiple Myeloma
Sponsor:
Barbara Ann Karmanos Cancer Institute
Organization:
Barbara Ann Karmanos Cancer Institute
Study Overview
Official Title:
Strategies to Isolate and Expand Myeloma Specific T-cells Using Autologous B Cells as Antigen Presenting Cell B-APC
Status:
TERMINATED
Status Verified Date:
2015-12
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Funding unavailable
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
RATIONALE Studying samples of blood and bone marrow from patients with cancer in the laboratory may help doctors learn more about T cells and plan better treatment for multiple myeloma
PURPOSE This research study is looking at T cells in blood and bone marrow samples from patients with multiple myeloma
PURPOSE This research study is looking at T cells in blood and bone marrow samples from patients with multiple myeloma
Detailed Description:
OBJECTIVES
Primary
To evaluate the feasibility of expanding myeloma-specific T cells using autologous ex vivo expanded B cells loaded with myeloma antigens as antigen-presenting cells B-APCs in peripheral blood and bone marrow samples from patients with multiple myeloma
Secondary
To examine the feasibility of selecting and expanding myeloma-specific T cells ex vivo using interferon γ release and CD3CD28 stimulation
OUTLINE Peripheral blood and bone marrow samples are collected periodically for laboratory studies Samples are analyzed to assess the feasibility of expanding autologous B cells ex vivo using CD40L and IL-4 the antigen-presenting phenotype of autologous B-cell antigen-presenting cells B-APCs using flow cytometry and the antigen-presenting function of B-APCs using ELISPOT and chromium-release assay Myeloma-specific interferon γ secreting T cells are isolated and selected using Miltenyi beads The selected myeloma-specific T cells are expanded ex vivo using anti CD3CD28 beads
Primary
To evaluate the feasibility of expanding myeloma-specific T cells using autologous ex vivo expanded B cells loaded with myeloma antigens as antigen-presenting cells B-APCs in peripheral blood and bone marrow samples from patients with multiple myeloma
Secondary
To examine the feasibility of selecting and expanding myeloma-specific T cells ex vivo using interferon γ release and CD3CD28 stimulation
OUTLINE Peripheral blood and bone marrow samples are collected periodically for laboratory studies Samples are analyzed to assess the feasibility of expanding autologous B cells ex vivo using CD40L and IL-4 the antigen-presenting phenotype of autologous B-cell antigen-presenting cells B-APCs using flow cytometry and the antigen-presenting function of B-APCs using ELISPOT and chromium-release assay Myeloma-specific interferon γ secreting T cells are isolated and selected using Miltenyi beads The selected myeloma-specific T cells are expanded ex vivo using anti CD3CD28 beads
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| P30CA022453 | NIH | None | None |
| WSU-2007-070 | US NIH GrantContract | None | httpsreporternihgovquickSearchP30CA022453 |